Drug Pricing

What kinds of policies helped the US surpass Great Britain to become the world’s center of pharmaceutical innovation? I think it was a combination of shrewd reforms on the part of the United States, and self-destructive reforms on the part of Europe and other developed nations. In the 1970s, Europe ...

Last week, the United States and the United Kingdom announced a trade deal that will require Britain’s National Health Service to pay more for novel prescription drugs in exchange for a reprieve of at least three years from tariffs on its pharmaceutical exports. It’s a perfect example of how the ...

Novo Nordisk just announced price cuts for Ozempic and Wegovy, whose list prices as recently as last year were around $1,000 a month. Patients buying directly from the manufacturer will be able to pay as little as $349 for a monthly dose of these medicines. The company has also dropped ...

Prices for GLP-1 weight-loss medications are dropping fast. Last week, Novo Nordisk—maker of Ozempic and Wegovy—announced it would cut prices for monthly supplies of both drugs to as low as $349 for existing patients buying directly. For new customers, the price will fall to just $199 a month for the ...

The conclusion of the longest government shutdown in history and rising political acrimony rightly receives a great deal of attention but this focus makes it easy to overlook areas where beneficial legislation is politically possible. The broad political agreement that it is necessary to reform how pharmacy benefit managers (PBM) ...

Members of the Senate Health, Education, Labor, and Pensions Committee held a hearing in October to discuss a federal healthcare policy long overdue for reform — the 340B Drug Pricing Program. Created to expand access to affordable medicines for low-income people, 340B has since fallen victim to rampant abuse by ...

The Trump administration has yet to decide whether Medicare will cover a revolutionary new class of weight-loss treatments, which include drugs like Zepbound and Wegovy. But a decision could be imminent, according to Dr. Mehmet Oz, head of the Centers for Medicare and Medicaid Services. Speaking at an event at ...

Since taking office in January, President Trump has wasted little time advancing health policies he hopes will lower costs, improve quality, and promote innovation. Those are goals worth supporting, to be sure. But the results of his efforts to date have been mixed. Consider Trump’s approach to prescription drug prices. ...

For millions of Americans, the new class of GLP-1 weight-loss drugs are as close to a miracle as modern medicine gets. Sold under brand names like Wegovy and Zepbound, these drugs have proven astoundingly successful at helping patients shed pounds. Unfortunately, a number of unscrupulous companies have sought to capitalize ...

The Trump administration wants to enable more Americans to purchase prescription medications directly from manufacturers at transparent, discounted prices—thus collectively saving patients tens of billions of dollars by cutting out middlemen in the drug supply chain. Voters overwhelmingly like the president’s idea. In a recent poll, 90% of Republican voters ...